Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder [Yahoo! Finance]
Addex Therapeutics Ltd - American Depositary Shares (ADXN)
Company Research
Source: Yahoo! Finance
Addex Therapeutics and Indivior PLC (NASDAQ: INDV ) announced that they have selected clinical candidates from their GABAB-positive allosteric modulator (PAM) research collaboration Indivior has selected a compound for future development in substance use disorder and will now undertake all future development of their selected compound. Under the terms of the agreement, Addex is eligible for payment of up to $330 million on achievement of prespecified regulatory, clinical and commercial milestones as well as tiered royalties on the level of net sales from high single digits up to low double-digit. Under the terms of the agreement, Addex has also exercised its right to select a compound to advance its own independent GABAB PAM program for chronic cough. “Indivior's collaboration with Addex has been instrumental in identifying a possible candidate for the treatment of substance use disorders,” said Christian Heidbreder, Chief Scientific Officer at Indivior.” “The selection of
Show less
Read more
Impact Snapshot
Event Time:
ADXN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADXN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADXN alerts
High impacting Addex Therapeutics Ltd - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ADXN
News
- Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net ProfitGlobeNewswire
- Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference [Yahoo! Finance]Yahoo! Finance
- Addex to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- Addex Therapeutics Ltd (NASDAQ: ADXN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research CollaborationGlobeNewswire
ADXN
Sec Filings
- 9/19/24 - Form 6-K
- 8/27/24 - Form 6-K
- 8/14/24 - Form SC
- ADXN's page on the SEC website